Health Care Related Organization
UnitedHealth’s Optum Defends $3.3 Billion Acquisition of Amedisys Amid DOJ Lawsuit
Optum, Amedisys, UnitedHealth, DOJ, Acquisition, Healthcare, Antitrust
Novartis Joins Eurovision 2025 as Official Partner
Eurovision 2025, Novartis, Official Partner, Basel, Switzerland
Roche and Flare Therapeutics Launch $1.8B-Plus Cancer Collaboration Targeting Transcription Factors
Roche, Flare Therapeutics, transcription factors, cancer drugs, oncology, biotech collaboration
Pfizer Weighs Sale of Hospital Drugs Unit Amid Activist Pressure
Pfizer, hospital drugs unit, sale, activist investor, Starboard Value, Goldman Sachs
GSK Exits Biotechnology Innovation Organization (BIO) for 2025, Joining Takeda, UCB, and Others
GSK, BIO, Biotechnology Innovation Organization, Takeda, UCB, Pfizer, WuXi AppTec, AbbVie, pharmaceutical industry, trade group, lobbying
AstraZeneca and Amgen’s Tezspire Shows Efficacy in Phase 3 Trial for Chronic Rhinosinusitis with Nasal Polyps, Despite Regulatory Risk Concerns
Tezspire, AstraZeneca, Amgen, Chronic Rhinosinusitis with Nasal Polyps (CRSwNP), Phase 3 Trial, Regulatory Risk
Tezspire Shows Promise in Treating Chronic Rhinosinusitis with Nasal Polyps
Tezspire, chronic rhinosinusitis with nasal polyps (CRSwNP), AstraZeneca, Amgen, WAYPOINT trial, TSLP inhibitor, nasal congestion, nasal polyps.
Eisai Slashes Leqembi Sales Forecast Amid Continued Launch Challenges
Eisai, Leqembi, Alzheimer’s disease, sales forecast, revenue expectations, Biogen, pharmaceutical industry
Pharmaceutical Giants Eli Lilly and Novo Nordisk Face Challenges Despite Strong Sales Growth
Eli Lilly, Novo Nordisk, Q3 2024 financial results, Obesity drugs, Weight loss therapies, Pharmaceutical industry challenges, Market competition, Supply pressures, Pricing issues
Trump’s Return to the White House: Potential Implications for FDA and Biopharma M&A
Trump, FDA, Biopharma, M&A, Healthcare Policy, Robert F. Kennedy Jr.